Wasik M A, Sackstein R, Novick D, Butmarc J R, Zhang Q, Vonderheid E C, Kadin M E
Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.
Hum Pathol. 1996 Jul;27(7):738-44. doi: 10.1016/s0046-8177(96)90408-6.
We report the case of a patient with a clinically aggressive large cell lymphoma (LCL) which expressed several T-lymphocyte markers and, in addition, CD56 and, to a lesser degree, CD68 antigens. A marked increase in serum concentration of interleukin (IL)-2 was found (490 and 167 pg/0.1 mL in two serum samples collected 6 months apart). This increase in IL-2 appeared unique to this lymphoma because serum concentration of IL-2 was not increased in any of the cases of various types of cutaneous lymphoproliferative disorders tested: mycosis fungoides-related cutaneous T-cell lymphoma (CTCL: 28 patients), granulomatous slack-skin syndrome (GS-SS: 1 patient), anaplastic large cell lymphoma (ALCL: 2 patients), subcutaneous gamma/delta T-cell lymphoma (gamma/delta-TCL: 1 patient), adult-type leukemia/lymphoma (ATLL: 1 patient), and lymphomatoid papulosis (LyP: 4 patients). Furthermore, the increase in IL-2 serum concentration appeared selective in this CD56+ large-cell lymphoma-bearing patient, because concentration of none of the five other cytokines tested (IL-4, IL-6, IFNgamma, GM-CSF, and TNFalpha) was increased. In contrast, soluble receptors for IL-2 and two of the other cytokines (IL-6, and TNFalpha) were markedly increased not only in this patient, but also in most patients with the other cutaneous lymphoproliferative disorders that we examined except for lymphomatoid papulosis. These data indicate that increased IL-2 serum concentration may help to diagnose a unique type of cutaneous CD56(+) large (T-) cell lymphoma and suggest that IL-2 way play a role of an autocrine growth factor for this lymphoma.
我们报告了一例临床侵袭性大细胞淋巴瘤（LCL）患者，该肿瘤表达多种T淋巴细胞标志物，此外还表达CD56，且CD68抗原表达较弱。发现血清白细胞介素（IL）-2浓度显著升高（在间隔6个月采集的两份血清样本中分别为490和167 pg/0.1 mL）。IL-2的这种升高似乎为此淋巴瘤所特有，因为在所检测的各种类型皮肤淋巴增生性疾病的任何病例中，IL-2血清浓度均未升高：蕈样肉芽肿相关皮肤T细胞淋巴瘤（CTCL：28例患者）、肉芽肿性皮肤松弛综合征（GS-SS：1例患者）、间变性大细胞淋巴瘤（ALCL：2例患者）、皮下γ/δ T细胞淋巴瘤（γ/δ-TCL：1例患者）、成人型白血病/淋巴瘤（ATLL：1例患者）以及淋巴瘤样丘疹病（LyP：4例患者）。此外，在这位携带CD56 +大细胞淋巴瘤的患者中，IL-2血清浓度的升高似乎具有选择性，因为所检测的其他五种细胞因子（IL-4、IL-6、IFNγ、GM-CSF和TNFα）的浓度均未升高。相比之下，不仅该患者，而且在我们检查的除淋巴瘤样丘疹病之外的大多数其他皮肤淋巴增生性疾病患者中，IL-2以及其他两种细胞因子（IL-6和TNFα）的可溶性受体均显著升高。这些数据表明，血清IL-2浓度升高可能有助于诊断一种独特类型的皮肤CD56(+)大（T-）细胞淋巴瘤，并提示IL-2可能作为该淋巴瘤的自分泌生长因子发挥作用。
